Oppenheimer & Co’s Foundation Medicine, Inc. FMI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
-12,535
Closed -$1.71M 1423
2018
Q2
$1.71M Sell
12,535
-700,305
-98% -$63.6M 0.05% 430
2018
Q1
$56.1M Sell
712,840
-120
-0% -$8.86K 1.44% 4
2017
Q4
$48.6M Sell
712,960
-10,520
-1% -$546K 1.25% 7
2017
Q3
$29.1M Buy
723,480
+39,390
+6% +$1.52M 0.78% 14
2017
Q2
$27.2M Buy
684,090
+9,050
+1% +$331K 0.75% 17
2017
Q1
$21.8M Sell
675,040
-28,541
-4% -$712K 0.62% 23
2016
Q4
$12.5M Sell
703,581
-17,690
-2% -$381K 0.36% 66
2016
Q3
$16.8M Buy
721,271
+47,350
+7% +$1.07M 0.49% 42
2016
Q2
$12.6M Buy
673,921
+251,370
+59% +$4.54M 0.37% 66
2016
Q1
$7.68M Buy
422,551
+24,710
+6% +$398K 0.23% 96
2015
Q4
$8.38M Buy
397,841
+15,500
+4% +$299K 0.25% 94
2015
Q3
$7.05M Buy
382,341
+198,982
+109% +$4.97M 0.21% 108
2015
Q2
$6.21M Buy
183,359
+91,439
+99% +$3.68M 0.17% 134
2015
Q1
$4.42M Sell
91,920
-2,399
-3% -$109K 0.12% 197
2014
Q4
$2.1M Buy
94,319
+69,360
+278% +$1.6M 0.06% 373
2014
Q3
$473K Buy
24,959
+13,889
+125% +$331K 0.01% 872
2014
Q2
$299K Buy
+11,070
New +$281K 0.01% 1054

Oppenheimer & Co's FMI Position: Q3 2018 in Review

Oppenheimer & Co sold out of Foundation Medicine, Inc. (FMI) in Q3 2018, closing a stake of 12,535 shares — an estimated $1.71M sold.

Oppenheimer & Co first reported a position in FMI in Q2 2014 and held it in 17 quarters. The position peaked at $56.1M in Q1 2018. 0 funds tracked by Wall St. Rank hold FMI as of Q3 2018.

  • Oppenheimer & Co reported no remaining Foundation Medicine, Inc. position as of Q3 2018 after selling out during the quarter.
  • Oppenheimer & Co sold 12,535 Foundation Medicine, Inc. shares in Q3 2018, an estimated $1.71M.
  • Oppenheimer & Co first reported a position in Foundation Medicine, Inc. in Q2 2014 and held it in 17 quarters.
  • Oppenheimer & Co's Foundation Medicine, Inc. position peaked at $56.1M in Q1 2018.
  • 0 funds tracked by Wall St. Rank held Foundation Medicine, Inc. as of Q3 2018.

Based on Oppenheimer & Co's 13F filing for Q3 2018, filed 26 Oct 2018.